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Medicine in the Young (Part 2)  
Maurice Hall and Lezley-Anne Hanna 
Lecturer (Education) and Senior Lecturer (Education), respectively; Queen’s University Belfast 
 
After completing this part of the module you will: 
• have an awareness of some statistics relating to medicines use in children 
• appreciate the difference between the terms ‘unlicensed’ and ‘off-label’  
• be able to discuss the general principles that should apply when unlicensed or off-label 
medicines are prescribed  
• know which over-the-counter (OTC) medicines are not suitable for use in children 
 
Introduction 
The previous article (Part 1) outlined the important pharmacokinetic characteristics in the developing 
child that need to be accounted for when using medicines in children. Having a fundamental 
knowledge of these pharmacokinetic factors is important in ensuring that medicines are used safely 
and effectively. This article (Part 2), aims to focus specifically on the use of medicines in children, 
looking particularly at factors pharmacists should consider when providing over-the-counter 
medicines for use in children.  
 
Statistics 
In England, those aged under 19 years were estimated to make up 22.5% of the population in 2015, 
while only being responsible for 4.5% of the total number of items dispensed. Conversely, those aged 
60 and over, made up 23% of the population, but accounted for 60.4% of the items dispensed. Even 
though the young do account for proportionately less medicine use, they have distinctive 
characteristics that make them an important group to consider. Furthermore, there are many over-
the-counter (OTC) medicines available for use in children and in Britain in 2015, OTC sales of paediatric 
analgesics totalled £83.5 million.  
Medicine use 
Prescribing medicines for children 
 
The prescribing of medicines for children has historically been difficult due to the lack of information 
regarding the use of medicines in children. In order to get a licence to promote the use of a medicine 
in children, the manufacturer has to conduct clinical trials that involve children; these can prove 
difficult and there are a number of ethical issues that have to be considered. Hence, it is relatively 
common for unlicensed or off-label medicines to be used in the young.  
• Unlicensed medicines are medicines that do not have a UK marketing authorisation and are 
not expected to acquire one in the next 2 years 
• Off-label medicines are medicines with existing UK marketing authorisations that are used 
outside the terms of their marketing authorisation, for example, by indication, dose, route or 
patient population and are not expected to get a marketing authorisation to cover this use in 
the next 2 years 
 
When medicines are being prescribed for any patient in an unlicensed or off-label context, the 
prescriber should ensure that: 
• No alternative appropriately licensed medicine exists 
• There is sufficient evidence or experience of using the medicine to know it is safe and 
effective 
• They take responsibility for prescribing the medicine and overseeing the patient’s care, 
including monitoring and follow-up 
• They record the medicine being prescribed and the rationale for prescribing it 
 
The process should involve patient or carer input and information regarding the treatment, including 
possible adverse effects, should be given so they can make an informed decision. It should be noted 
that doctors, dentists, independent nurse prescribers, independent pharmacist prescribers and 
supplementary prescribers can all prescribe unlicensed medicines or use off-label medicines, whereas 
optometrists, therapeutic radiographers, physiotherapists and podiatrists who are independent 
prescribers are not permitted to prescribe unlicensed medicines but may prescribe medicines off-
label. 
 
A number of medicines should be avoided in children or should be used with caution given the 
increased potential for adverse reactions or toxicity. Examples of such drugs are shown in Table 1. 
 
Table 1 Medicines with notable effects in children (see also Table 2 for OTC medicines) 
 
Antihistamines (sedating) –  children are more susceptible to side-effects. Can rarely cause 
paradoxical excitement. Use in the latter part of the third trimester may cause adverse effects in 
neonates such as irritability, paradoxical excitability, and tremor 
Arachis oil (for treatment of scalp conditions) – best avoided in children under 5 
Benzyl benzoate –avoid in children due to its irritant nature 
Chloramphenicol – avoid in neonates due to risk of Grey syndrome  
Corticosteroids - long-term use in prepubertal children can cause growth suppression 
Danazol – avoid in children due to androgenic effects 
Glibenclamide – avoid in children due to increased risk of hypoglycaemia 
Iron – children are at increased risk of iron toxicity, with iron preparations being an important 
cause of accidental overdose in children 
Lamotrigine – can cause severe skin reactions, especially in children 
Phenobarbital – can cause paradoxical hyperactivity in children  
Sodium valproate – where possible, avoid in children under 2 (especially if taking other 
antiepileptics) 
Sulphonamide antibiotics – risk of kernicterus due to displacement of bilirubin from binding sites 
on plasma albumin 
Tetracyclines – avoid in children under 12 due to enamel hypoplasia and permanent 
discolouration of the teeth 
 
 
OTC medicines 
As previously stated, there is a plethora of OTC medicines available for use in children. However, there 
are also many instances when OTC medicines are not suitable for children or when guidance has been 
released about specific OTC medicines. It is important to have up-to-date knowledge of this area given 
that a fundamental responsibility of the community pharmacist relates to the safe and effective use 
of medicines, including OTC medicines. Table 2 outlines conditions or OTC medicines associated with 
particular guidance (and also provides examples of key groups of medicines that should be avoided in 
children).  
Table 2 Over-the-counter (OTC) medicines with particular guidance in relation to use in children 
(or examples of key groups of medicines that should be avoided) 
Subject area Medicines associated with guidance/key groups of medicines to be avoided 
Respiratory Medicines and Healthcare products Regulatory Agency (MHRA) guidance on cough and 
cold products 
https://www.gov.uk/drug-safety-update/over-the-counter-cough-and-cold-medicines-for-
children 
Following a scientific review of the evidence about 7 or 8 years ago, cough and cold 
ingredients such as pseudoephedrine, ephedrine, guaifenesin, pholcodine are not suitable 
for use in under 6 years because the risks (side-effect profile) outweighs the benefits. 
Many of these products lack a robust evidence-base.  
Current best practice for managing cough and colds in children aged under 6 years:  
Simple measures such as ensuring your child has plenty to drink and gets enough rest will 
help. Paracetamol or ibuprofen can also be used to reduce temperature (see other fever 
guidance below). Nasal saline may help thin and clear nasal secretions. Child >1 year, a 
warm drink of lemon and honey may help to ease a cough. No better after about 5 days, 
ask a healthcare professional for advice. 
Current best practice for managing cough and colds in children aged 6-12 years:  
OTC cough and cold medicines can be considered after basic principles of best care have 
been tried (see above). Treatment should be restricted to 5 days or less. Care should be 
taken to give the correct dose. Children should not be given more than one cough or cold 
preparation at a time because different brands may contain the same active ingredient. 
NB The MHRA guidance on cough and cold products only applies to products that have 
licensed indications for cough and cold. For example, chlorphenamine is on their restricted 
list but when it is in Piriton® it is okay to sell to children over 1 year. Piriton® is licensed for 
hay fever and other allergies (including itchy skin rash of chickenpox) but has no indication 
for cough and cold. 
Honey: is not suitable under 12 months of age (infant botulism risk). 
http://www.nhs.uk/conditions/pregnancy-and-baby/pages/foods-to-avoid-baby.aspx 
Codeine: Previous MHRA advice (2010) stated that over-the-counter oral liquid medicines 
containing codeine should no longer be used to treat cough in children and young people 
under 18 years. In addition, all over-the-counter oral liquid codeine medicines were to be 
supplied in child-resistant containers. 
http://www.mhra.gov.uk/home/groups/spar/documents/websiteresources/con096798.p
df 
However, in 2015, the MHRA issued the following guidance about codeine in cough and 
cold products: “Do not use codeine in children under 12 as it is associated with a risk of 
respiratory side effects. Codeine is not recommended for adolescents (12 to 18) who have 
problems with breathing”. 
https://www.gov.uk/drug-safety-update/codeine-for-cough-and-cold-restricted-use-in-
children 
Oral echinacea herbal products: the MHRA issued guidance on this a few years ago (2012) 
not recommended for use in under 12 years (allergic reactions). 
http://webarchive.nationalarchives.gov.uk/20141205150130/http://www.mhra.gov.uk/N
ewsCentre/Pressreleases/CON180627 
See NICE pathway on self-limiting respiratory tract infections 
https://pathways.nice.org.uk/pathways/self-limiting-respiratory-tract-infections---
antibiotic-prescribing  
Allergic rhinitis: OTC corticosteroid intranasal preparations are usually not suitable for use 
in under 18 years 
https://www.medicines.org.uk/emc/medicine/14212 
https://www.medicines.org.uk/emc/medicine/21565 
Women’s 
Health 
Cystitis remedies: while products may be licensed for use in children, best practice centres 
on referral for further investigation (rather than recommending OTC products). 
Uncomplicated cystitis is not common in children so could be a structural abnormality, 
urinary tract infection or abuse. See also NICE pathway on urinary tract infections in 
children and young people. 
https://www.nice.org.uk/guidance/qs36 
Vaginal candidiasis (thrush): refer under 16 years due to product licence restrictions 
OTC naproxen 250mg tablets for primary dysmenorrhoea are licensed for 15-50 years  
OTC tranexamic acid 500mg tablets for heavy menstrual bleeding are not licensed for use 
in under 18 years. 
OTC emergency contraception: Levonelle One Step– not for under 16 years whereas 
ellaOne manufacturer states it “is suitable for any woman of child bearing age, including 
adolescents.” (therefore appropriate legislation and pertinent guidance such as that 
provided by the Department of Health and pharmacy regulatory and professional bodies 
should be considered if recommending it to a patient under the legal age of consent to any 
form of sexual activity).  
https://www.medicines.org.uk/emc/medicine/15227 
https://www.medicines.org.uk/emc/medicine/22280 
See also: http://www.fpa.org.uk/factsheets/law-on-sex 
 
Gastro-
intestinal 
Constipation – NICE pathway recommends that children have a physical examination done 
as part of the diagnosis stage.  
https://www.nice.org.uk/guidance/cg99?unlid=97695977201610274347 
Diarrhoea –NICE have published guidance on managing gastroenteritis (diarrhoea and 
vomiting) in children under 5 years, including an ‘assessing dehydration chart’ 
https://pathways.nice.org.uk/pathways/diarrhoea-and-vomiting-in-children 
OTC Proton pump inhibitors (omeprazole, esomeprazole, pantoprazole) tend to be not 
licensed for under 18 years whereas OTC H2 antagonist (ranitidine) tend to not be 
licensed for under 16 years but this shouldn’t be an issue given heartburn is not common 
in children (excluding reflux in babies) 
OTC loperamide is not suitable for use in under 12 years (care with Imodium products – 
must be 18 years+ to use it for acute episodes of diarrhoea linked to irritable bowel 
syndrome) 
Haemorrhoid preparations containing hydrocortisone such as Anusol® HC tend not to be 
licensed for use in under 18 years (Germaloids® HC spray is not for use in under 16 years). 
This shouldn’t cause problems in practice since haemorrhoids are not common in children. 
https://www.medicines.org.uk/emc/medicine/8463 
https://www.medicines.org.uk/emc/PIL.21846.latest.pdf 
 
Travel Chloroquine dosing for antimalarial chemoprophylaxis: theoretical versus OTC product 
dosing may not align. If this is the case, refer patient to the doctor to be prescribed the 
appropriate dose rather than recommending the OTC product out of licence.  
[assuming that chlorquine is the appropriate choice in the first instance] 
Pain Paracetamol: age ranges and doses changed (2011), but not for safety reasons per se 
http://www.nhs.uk/news/2011/11November/Pages/new-child-calpol-paracetamol-
doses.aspx 
Codeine is contra-indicated for use in under 12 years (toxicity risk) 
https://www.gov.uk/drug-safety-update/codeine-for-analgesia-restricted-use-in-children-
because-of-reports-of-morphine-toxicity 
Aspirin is contra-indicated for use in under 16 years (Reye’s syndrome risk) unless given 
under the advice of a doctor. This also applies to oral salicylates such as choline salicylate 
and bismuth subsalicylate. 
OTC sumatriptan is only for 18-65 age range 
Ear Acute otitis media (AOM) – follow NICE guidance regarding offering simple analgesia for 
pain relief and fever (paracetamol or ibuprofen) and providing the correct information on 
immediate versus delayed antibiotic prescribing, given that many cases resolve without 
the need for antibiotics. 
http://cks.nice.org.uk/otitis-media-acute#!scenario 
Otitis externa: OTC Earcalm (acetic acid 2%) is indicated for the treatment of superficial 
infections of the external auditory canal but is not suitable for use in under 12 years 
https://www.medicines.org.uk/emc/medicine/17298 
Eye Topical OTC chloramphenicol may not be licensed for use in under 2 years, depending on 
the specific manufacturer (one such example is Optrex® Bacterial Conjunctivitis 1% w/w 
Eye ointment) https://www.medicines.org.uk/emc/medicine/32184 
However, Brolene® Antibiotic 1.0% w/w Eye Drops SPC states to “talk to your doctor 
before giving this medicine to a newborn infant. Dosage adjustment may be necessary.” 
https://www.medicines.org.uk/emc/medicine/30103 
Mouth Daktarin sf 2% oral gel for oral thrush has an age limit (4 months) due to choking risk. 
However, it is also contra-indicated in those whose swallowing reflex is not sufficiently 
developed. https://www.medicines.org.uk/emc/medicine/22032 
Some chlorhexidine-containing mouthwashes have an age limit of 12 years (unless 
recommended by your dentist) 
https://www.medicines.org.uk/emc/PIL.24660.latest.pdf 
Skin Be aware that the US Food and Drug Administration (FDA) has approved the first OTC 
retinoid treatment for acne (Adapalene – Differin® Gel 0.1%) in the US for patients aged 
12 years and over. 
http://www.medscape.com/viewarticle/865918.  
Topical corticosteroids such as HC45® cream (hydrocortisone acetate BP 1.0% w/w) are 
not licensed for use in under 10 years without medical advice. Other products such as 
Eumovate Eczema and Dermatitis Cream® (clobetasone butyrate 0.05 % w/w) are not for 
use in under 12 years without medical advice 
https://www.medicines.org.uk/emc/medicine/23417 
https://www.medicines.org.uk/emc/medicine/16111 
Lyclear Dermal Cream is indicated for the treatment of scabies in adults and children >2 
months of age, and crab lice in adults. But the manufacturer also states: only limited 
experience is available with Lyclear Dermal Cream in children aged 2 months to 23 
months. Therefore, treatment must be given only under close medical supervision in this 
age group. https://www.medicines.org.uk/emc/medicine/10439 
Childhood 
conditions 
Be familiar with NICE fever management (antipyretics such as paracetamol or ibuprofen 
not routinely advocated unless child is also distressed). See NICE for current guidance on 
alternating doses of ibuprofen and paracetamol. 
https://pathways.nice.org.uk/pathways/feverish-illness-in-children 
and how to recognise the signs of meningitis and sepsis 
http://www.nhs.uk/Conditions/Meningitis/Pages/Symptoms.aspx 
http://www.nhs.uk/conditions/Blood-poisoning/Pages/Introduction.aspx 
Post-immunisation pyrexia: care with OTC paracetamol license versus current guidance on 
paracetamol use in relation to the Meningitis B vaccine 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/483408/
9413-paracetamol-menB-2page-A4-08-web.pdf 
Information about the UK childhood immunisation schedule is available: 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/554298/
Green_Book_Chapter_11.pdf 
Paracetamol: age ranges and doses changed (2011), but not for safety reasons per se 
http://www.nhs.uk/news/2011/11November/Pages/new-child-calpol-paracetamol-
doses.aspx 
Ibuprofen is not suitable for pain or fever management in chickenpox (only paracetamol) 
due to potential increased risk of necrotising soft tissue infection and invasive group A 
streptococcal infections. 
http://www.gponline.com/chickenpox-varicella-zoster-clinical-review/infections-and-
infestations/viral-infections/article/1284872 
 
 
 
Conclusion:  
Pharmacists are well placed to ensure medicine use in the young is safe, effective and, as much as is 
possible, evidence-based (regardless as to whether it is a prescribed or OTC medicine). Given the 
vulnerable nature of children with their distinctive physiology and age-related drug handling 
capabilities, it is important that all healthcare professionals, including pharmacists, ensure that the 
benefits of any medicine are not outweighed by the risks. Therefore, having a fundamental knowledge 
of pharmacokinetics in children (at various stages of childhood), coupled with utilising reliable 
evidenced-based resources and having a sound understanding of key pieces of legislation is essential. 
Future research should focus on expanding the evidence-base for unlicensed or off-label medicine use 
in children so that clinical decision-making is better informed. 
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